Truvestments Capital LLC Makes New $32,000 Investment in Sensus Healthcare, Inc. (NASDAQ:SRTS)

Truvestments Capital LLC purchased a new position in Sensus Healthcare, Inc. (NASDAQ:SRTS) in the 3rd quarter, HoldingsChannel.com reports. The firm purchased 5,511 shares of the company’s stock, valued at approximately $32,000.

A number of other large investors also recently modified their holdings of the business. Chapin Davis Inc. bought a new position in shares of Sensus Healthcare in the second quarter valued at approximately $53,000. Acadian Asset Management LLC lifted its position in Sensus Healthcare by 578.6% in the second quarter. Acadian Asset Management LLC now owns 45,124 shares of the company’s stock worth $239,000 after purchasing an additional 38,474 shares during the period. Sachetta LLC boosted its stake in Sensus Healthcare by 12.9% during the 2nd quarter. Sachetta LLC now owns 118,354 shares of the company’s stock valued at $631,000 after purchasing an additional 13,544 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of Sensus Healthcare by 128.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 166,590 shares of the company’s stock valued at $888,000 after purchasing an additional 93,511 shares during the period. Finally, Renaissance Technologies LLC raised its stake in shares of Sensus Healthcare by 34.4% in the 2nd quarter. Renaissance Technologies LLC now owns 391,534 shares of the company’s stock worth $2,087,000 after buying an additional 100,294 shares in the last quarter. 25.30% of the stock is owned by institutional investors and hedge funds.

Sensus Healthcare Stock Down 0.1 %

SRTS opened at $8.60 on Thursday. The firm has a market cap of $140.95 million, a PE ratio of 15.09 and a beta of 1.04. The business has a fifty day simple moving average of $6.80 and a 200-day simple moving average of $6.22. Sensus Healthcare, Inc. has a fifty-two week low of $2.05 and a fifty-two week high of $9.33.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. HC Wainwright lifted their target price on Sensus Healthcare from $10.00 to $11.00 and gave the stock a “buy” rating in a report on Monday, November 18th. Maxim Group lifted their price objective on shares of Sensus Healthcare from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Friday, November 15th.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.